Toll Free: 1-888-928-9744

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016

Published: May 18, 2016 | Pages: 33 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Review, H1 2016', provides in depth analysis on Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted pipeline therapeutics. 

The report provides comprehensive information on the Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10)
- The report reviews Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) Overview 6 Therapeutics Development 7 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Stage of Development 7 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Therapy Area 8 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Indication 9 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Products under Development by Companies 12 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Companies Involved in Therapeutics Development 19 GlaxoSmithKline Plc 19 Sphaera Pharma Pvt. Ltd. 20 Sumitomo Dainippon Pharma Co., Ltd. 21 Toray Industries, Inc. 22 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Drug Profiles 23 (diclofenac sodium + triclocarban) - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 EC-5026 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 GSK-2256294 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Small Molecules to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Dormant Projects 30 Soluble Epoxide Hydrolase (Epoxide Hydratase or Aryl Epoxide Hydrase or EC 3.3.2.10) - Featured News & Press Releases 31 Aug 19, 2013: Sphaera Pharma completes phase I trials for neuropathic pain drug 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 18 Pipeline by GlaxoSmithKline Plc, H1 2016 19 Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 20 Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 21 Pipeline by Toray Industries, Inc., H1 2016 22 Dormant Projects, H1 2016 30


List of Figures
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Top 10 Indication, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Actions, H1 2016 15 Number of Products by Routes of Administration, H1 2016 16 Number of Products by Stage and Routes of Administration, H1 2016 16 Number of Products by Stage and Molecule Type, H1 2016 18

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify